Insmed (NSM) Doses First Patient in ARIKACE Phase 2
Insmed Incorporated (Nasdaq: INSM), announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease entitled TARGET-NTM (Treatment with ARIKACE to Realize Greater Efficacy Trial).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- iBio, Inc. (IBIO) Receives U.S. Patent Related to Fibrosis Treatment
- Myriad Genetics (MYGN) Announces Positive Results for myChoice HRD Test in TESARO (TSRO) Collaboration
- Baxter (BAX) Receives Health Canada Approval of AMIA APD System with SHARESOURCE Connectivity Platform
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!